Keryx Biopharmaceuticals (NASDAQ:KERX) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.56 by 9 Brokerage Firm. 6 Wall Street Firms have rated the stock as a strong buys. 1 stock experts have also suggested a buy rating. 2 Brokerage Firms have advised hold.
Other Equity analysts have also commented on the company shares. Maxim Group maintains its view on Keryx Biopharmaceuticals (NASDAQ:KERX) according to the research report released by the firm to its investors. The shares have now been rated Buy by the stock experts at the ratings house. Maxim Group raises the price target from $5 per share to $7 per share on Keryx Biopharmaceuticals . The rating by the firm was issued on March 29, 2016.
Keryx Biopharmaceuticals (NASDAQ:KERX): According to 8 Analysts, The short term target price has been estimated at $ 8.75.The target price could deviate by a maximum of $2.92 from the forecast price. In the near term, the target price could hit a high of $13 and a low of $ 4.
Keryx Biopharmaceuticals (NASDAQ:KERX) witnessed a decline in the market cap on Tuesday as its shares dropped 1.31% or 0.08 points. After the session commenced at $6.14, the stock reached the higher end at $6.155 while it hit a low of $5.85. With the volume soaring to 1,188,222 shares, the last trade was called at $6.05. The company has a 52-week high of $10.51. The company has a market cap of $640 million and there are 105,820,947 shares in outstanding. The 52-week low of the share price is $2.8.
Shares of Keryx Biopharmaceuticals Inc. rose by 2.89% in the last five trading days and 5.4% for the last 4 weeks. Keryx Biopharmaceuticals Inc. is up 29% in the last 3-month period. Year-to-Date the stock performance stands at 19.8%.
Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. Its lead product Auryxia (ferric citrate), an oral, absorbable iron-based compound, received marketing approval from the United States Food and Drug Administration (FDA), for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. The approval of Auryxia was based on data from its Phase III registration program, in which Auryxia effectively reduced serum phosphorus levels to well within the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines range of 3.5 to 5.5 mg/dL. In addition to the effects on serum phosphorus levels, Auryxias pharmacodynamic properties resulted in increased ferritin, iron and transferrin saturation (TSAT).